The primary outcome was the composite of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke, analyzed as time to the first event. The secondary outcomes were (in listed order): all-cause mortality, any coronary event (defined as sudden death, fatal or nonfatal myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, ventricular defibrillation by an implantable cardioverter-defibrillator, resuscitation from cardiac arrest, or hospitalization for unstable angina), cardiovascular mortality (cause-specific cardiovascular death was also analyzed), and number (episodes) of hospitalizations (for cardiovascular causes, unstable angina, and worsening heart failure). The present report focuses on the primary end point, total mortality, the coronary end point, and hospitalizations (all-cause, cardiovascular cause, and worsening heart failure). We also included the additional post-hoc composite outcome of death from any cause or hospitalization for worsening heart failure (analyzed as time to first event) because of previously expressed concerns that coenzyme Q10 deficiency might cause worsening heart failure, leading to increased risk of hospital admission and death. We conducted further post-hoc analyses of patients hospitalized for all causes, cardiovascular causes, worsening heart failure, and noncardiovascular causes (analyzed as time to first event). The definition and adjudication of all outcomes have been described in detail previously (19- 20). As the result of a protocol amendment adopted 15 months after the start of the trial, patients also completed a questionnaire about muscle symptoms at each study visit and had a measurement of creatine kinase at 6 and 15 months after randomization, yearly thereafter, and at the last study visit (20). Patients were asked 2 questions: whether they had any muscular pain since the previous visit, and whether they had muscular pain at the present visit.